PCSK9 inhibitors in sepsis: a new potential indication?-Reference-Cited by-同舟云学术

PCSK9 inhibitors in sepsis: a new potential indication?

Published:2016-12-21 Issue:2 Volume:26 Page:137-139
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Momtazi Amir Abbas¹,Banach Maciej²,Sahebkar Amirhossein³

Affiliation:

1. Student Research Committee, Nanotechnology Research Center, Department of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2. Department of Hypertension, WAM University Hospital in Lodz, Medical University of Lodz, Lodz, Poland

3. Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2017.1272570

Reference16 articles.

1. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors

2. New LDL-Cholesterol Lowering Therapies: Pharmacology, Clinical Trials, and Relevance to Acute Coronary Syndromes

3. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

4. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population

5. New Therapies Targeting apoB Metabolism for High-Risk Patients with Inherited Dyslipidaemias: What Can the Clinician Expect?

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of serum proprotein convertase subtilisin/kexin type 9 in pediatric sepsis syndrome;Scientific Reports;2024-07-07

2. Elevated circulating PCSK9 level is associated with 28-day mortality in patients with sepsis: a prospective cohort study;BMC Emergency Medicine;2023-10-31

3. The Association Between PCSK9 Inhibitor Use and Sepsis: A Systematic Review and Meta-Analysis of 20 Double-Blind, Randomized, Placebo-Controlled Trials;The American Journal of Medicine;2023-06

4. Preclinical toxicity assessment of a peptide-based antiPCSK9 vaccine in healthy mice;Biomedicine & Pharmacotherapy;2023-02

5. Biomarkers of Sepsis and a Focus on PCSK9;Biomarkers in Trauma, Injury and Critical Care;2023